TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07202546: A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of Oral VH4524184 Coadministered With Emtricitabine and Tenofovir Alafenamide in Treatment Naive Viremic Persons With HIV-1 (IN

Sponsor: ViiV Healthcare · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 186 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$352,800

Rescue Site Savings

+$235,200

Unlock Full NCT07202546 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07202546 Rescue Dossier →